Kadmon Co. (NYSE:KDMN) – Equities research analysts at Jefferies Group raised their Q1 2018 earnings per share (EPS) estimates for shares of Kadmon in a research note issued on Wednesday, according to Zacks Investment Research. Jefferies Group analyst B. Amin now expects that the company will post earnings of ($0.23) per share for the quarter, up from their prior estimate of ($0.50). Jefferies Group currently has a “Buy” rating and a $16.00 price target on the stock. Jefferies Group also issued estimates for Kadmon’s Q2 2018 earnings at ($0.24) EPS, Q3 2018 earnings at ($0.23) EPS, Q4 2018 earnings at ($0.24) EPS, FY2018 earnings at ($0.96) EPS, FY2019 earnings at ($1.06) EPS, FY2020 earnings at ($1.12) EPS, FY2021 earnings at ($1.20) EPS and FY2022 earnings at ($0.33) EPS.
Kadmon (NYSE:KDMN) last announced its quarterly earnings results on Tuesday, March 6th. The company reported ($0.24) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.12. The firm had revenue of $1.50 million for the quarter, compared to analyst estimates of $3.07 million. During the same period in the previous year, the business posted ($0.50) earnings per share. The business’s revenue for the quarter was down 65.1% compared to the same quarter last year.
A number of other analysts have also commented on the company. Zacks Investment Research raised Kadmon from a “strong sell” rating to a “hold” rating in a research note on Saturday, March 10th. HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of Kadmon in a research note on Friday, March 9th. Finally, Piper Jaffray reissued a “positive” rating and set a $9.00 price target (up from $7.00) on shares of Kadmon in a research note on Tuesday, February 13th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $11.45.
Shares of KDMN stock traded down $0.12 during mid-day trading on Friday, reaching $4.13. 318,412 shares of the stock traded hands, compared to its average volume of 997,782. Kadmon has a 1-year low of $2.05 and a 1-year high of $5.86. The firm has a market capitalization of $334.23, a price-to-earnings ratio of -2.91 and a beta of 3.90.
Several institutional investors and hedge funds have recently modified their holdings of KDMN. Wells Fargo & Company MN boosted its holdings in Kadmon by 17.0% during the second quarter. Wells Fargo & Company MN now owns 60,033 shares of the company’s stock worth $234,000 after buying an additional 8,742 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Kadmon by 166.0% in the second quarter. Vanguard Group Inc. now owns 1,508,869 shares of the company’s stock valued at $5,870,000 after buying an additional 941,549 shares during the last quarter. Goldman Sachs Group Inc. acquired a new position in shares of Kadmon in the second quarter valued at approximately $114,000. Bank of New York Mellon Corp acquired a new position in shares of Kadmon in the third quarter valued at approximately $119,000. Finally, AE Wealth Management LLC raised its position in shares of Kadmon by 33.6% in the third quarter. AE Wealth Management LLC now owns 323,161 shares of the company’s stock valued at $1,083,000 after buying an additional 81,226 shares during the last quarter. Institutional investors own 61.71% of the company’s stock.
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics within autoimmune and fibrotic, oncology, and genetic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including those indicated for the management of rare diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.